Autolus Therapeutics plc (NASDAQ:AUTL – Get Free Report)’s stock price traded down 5% during trading on Monday . The stock traded as low as $4.55 and last traded at $4.56. 47,927 shares changed hands during trading, a decline of 96% from the average session volume of 1,351,573 shares. The stock had previously closed at $4.80.
Autolus Therapeutics Stock Performance
The company has a fifty day moving average of $3.94 and a 200 day moving average of $4.11. The company has a debt-to-equity ratio of 0.09, a current ratio of 18.55 and a quick ratio of 18.55. The stock has a market cap of $1.21 billion, a P/E ratio of -3.76 and a beta of 2.04.
Autolus Therapeutics (NASDAQ:AUTL – Get Free Report) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.03). On average, equities analysts predict that Autolus Therapeutics plc will post -0.84 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Autolus Therapeutics
About Autolus Therapeutics
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.
Recommended Stories
- Five stocks we like better than Autolus Therapeutics
- Where to Find Earnings Call Transcripts
- Analysts Predict New Highs for Cybersecurity Stock by Christmas
- P/E Ratio Calculation: How to Assess Stocks
- Nuclear Power Reaches Critical Mass: Top Stocks to Watch Now
- What Are Growth Stocks and Investing in Them
- 2 Energy Stocks Surging on Billion-Dollar DOE Loan Commitments
Receive News & Ratings for Autolus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Autolus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.